Florida Links E. Coli and Campylobacter Outbreak to Raw Milk Farm
The agency said severe E. coli and campylobacter infections were tied to Keely Farms Dairy in New Smyrna Beach, Florida, on the eastern coast about 15 miles south of Daytona Beach.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
US FDA says country's IV, injectable saline shortage is resolved
(Reuters) -A shortage of intravenous and injectable saline solutions in the United States has now been resolved, U.S. Food and Drug Administration commissioner Martin Makary said on Friday. A shortage of IV fluids, which provide nutrients to the body or replenish fluids lost due to injury or illness, had forced hospitals to curtail elective procedures last year. The shortage partly stems from Baxter International's North Carolina plant getting damaged in Hurricane Helene in September. At that time, the Marion, North Carolina site was producing 60% of the nation's supply of IV fluids and peritoneal dialysis solutions, amounting to 1.5 million bags daily, according to the American Hospital Association. Baxter and the FDA did not immediately respond to Reuters' requests for comment. Germany's Fresenius and B. Braun Medical had ramped up their production to help mitigate these shortages, while Baxter worked with the FDA to import some intravenous products. Last week, the company said demand remained subdued, even as supply stabilized. In May, Baxter said inventory levels at its North Carolina facility had been fully restored. The FDA said it is working closely with manufacturers and will continue to monitor the supply of other IV fluids, which are still in shortage. Hurricane Helene struck the Florida Gulf Coast in late September, ripping up roads, destroying homes, severing communication across the southeastern U.S., and leaving hundreds unaccounted for and many confirmed dead. Many hospitals in Florida and Tennessee were forced to evacuate or operate under emergency conditions, while dealing with shortage of resources. Solve the daily Crossword
Yahoo
25 minutes ago
- Yahoo
Vycor Medical Releases Financial Results for the Three and Six Months Ended June 30, 2025
BOCA RATON, FL - August 8, 2025 (NEWMEDIAWIRE) - Vycor Medical, Inc. ("Vycor" or the "Company") (OTCQB-VYCO), today announced financial results for the three and six months ended June 30, 2025. The Company operates through two business units: Vycor Medical, which produces the ViewSite(TM) Brain Access System (VBAS) for neurosurgery; and NovaVision(R), a business in development which offers therapy programs to help patients recover from visual disorders after stroke or brain injury. Company Highlights The Vycor Medical division revenues for the three and six months ended June 30, 2025 increased by 24% and 28%, respectively, most of the increase being from growth in international markets. Operating profit for the three and six months ended June 30, 2025 was $51,146 and $38,340, respectively, and non-GAAP operating profit for the three and six months ended June 30, 2025 was $84,481 and $106,944, respectively, all substantial increases over the 2024 periods. Vycor entered into new distribution agreements for France and Spain during the six months ended June 30, 2025, two important markets targeted for international expansion. Two new clinical papers were published involving the ViewSite Brain Access System (VBAS) during the three months ended June 30, 2025 in addition to the three papers published during the first three months of the year, bringing the total published peer reviewed clinical papers to 48. The two studies published were systematic reviews of tubular retractors in general brain surgery and neuro-oncology surgery, respectively, and highlighted the clinical advantages of VBAS. A new clinical study on NovaVision's NeuroEyeCoach was published, comparing results from using the program at home or in a clinic. The study concluded that both home-based and clinic-based patients showed meaningful improvements with no significant differences in activities of daily living improvements, validating NeuroEyeCoach as an effective tool, whether used clinically or accessed remotely. This is an important study for the company given the significant drive in healthcare systems worldwide to access digital technologies in home settings. Financial Results For the three months ended June 30, 2025, the Company reported revenue of $496,353, an increase of $90,075 (or 22%) over the same period in 2024. The Vycor Medical division (VBAS) generated revenue of $481,788, an increase of $94,539 (or 24%) over the same period in 2024, most of the increase being from growth in international markets. The gross profit margin for 2025 was 83% versus 91% in 2024, with the lower gross margin in 2025 attributable to validation and shipping costs of new production as well as geographical sales mix. The NovaVision division, which remains in development, generated revenues of $14,565 for the three months ended June 30, 2025, versus $19,029 in 2024, and gross margin of 93%, compared to 95% for 2024. For the six months ended June 30, 2025, the Company reported revenue of $932,731, an increase of $189,485 (or 25%) over the same period in 2024. The Vycor Medical division (VBAS) generated revenue of $900,308, an increase of $194,501 (or 28%) over the same period in 2024, most of the increase being from growth in international markets. The gross profit margin for 2025 was 83% versus 90% in 2024, with the lower gross margin in 2025 attributable to validation and shipping costs of new production as well as sales mix. The NovaVision division, which remains in development, generated revenues of $32,423 for the six months ended June 30, 2025, versus $37,439 in 2024, and gross margin of 94%, compared to 93% for 2024. Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Revenue: Vycor Medical $481,788 $387,249 $900,308 $705,807 NovaVision 14,565 19,029 32,423 37,439 $496,353 $406,278 $932,731 $743,246 Gross Profit Vycor Medical $401,783 $352,963 $743,581 $636,039 NovaVision 13,488 18,152 30,224 35,038 $415,271 $371,115 $773,805 $671,077 For the three months ended June 30, 2025 the Company reported non-GAAP Cash Operating Expenses of $330,790 compared to $339,256 in 2024 and non-GAAP Operating Profit of $84,481 compared to $31,859 in 2024. For the six months ended June 30, 2025 the Company reported non-GAAP Cash Operating Expenses of $666,861 compared to $630,766 in 2024 and non-GAAP Operating Profit of $106,944 compared to $40,311 in 2024. Reconciliation of Non-GAAP Information Management uses certain non-GAAP financial measures (including non-GAAP operating expenses and non-GAAP net loss and loss per share), which exclude non-cash depreciation of purchased assets and non-cash stock-based compensation. Management does not consider these costs in evaluating the continuing operations of the Company. Therefore, management calculates the non-GAAP financial measures provided in this earnings release excluding these costs and uses these non-GAAP financial measures to enable it to analyze further, and more consistently, the period-to-period financial performance of its core business operations. Management believes that providing investors with these non-GAAP measures gives them additional important information to enable them to assess, in the same way management assesses, the Company's current and future continuing operations. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP. Set forth below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measures. Three months ended June 30, 2025 On a GAAP basis the Company reported Operating Expenses of $364,125, an operating profit of $51,146, a net income of $23,887 and net income of $0.00 per share. Vycor's GAAP operating costs include non-cash depreciation of purchased assets ($15,021) and non-cash stock compensation charges ($18,314). The Company is providing additional non-GAAP financial measures that exclude these charges and expenses, and reconciliation of GAAP to non-GAAP results is provided in the tables included in this release. On a non-GAAP basis, taking into account these adjustments, operating expenses were $330,790, non-GAAP operating profit was $84,481, and non-GAAP net income was $57,222 or $0.00 per share. Six months ended June 30, 2025 On a GAAP basis the Company reported Operating Expenses of $735,465, an operating profit of $38,340, a net loss of $176,861 and a loss of $0.01 per share. Vycor's GAAP operating costs include non-cash depreciation of purchased assets ($31,975) and non-cash stock compensation charges ($36,629). The Company is providing additional non-GAAP financial measures that exclude these charges and expenses, and reconciliation of GAAP to non-GAAP results is provided in the tables included in this release. On a non-GAAP basis, taking into account these adjustments, operating expenses were $666,861, non-GAAP operating profit was $106,944, and non-GAAP net loss was $108,257 or $0.00 per share. VYCOR MEDICAL, Statements of Comprehensive Loss(unaudited) For the three months ended June 30, For the six months ended June 30, 2025 2024 2025 2024 Revenue $496,353 $406,278 $932,731 $743,246 Cost of Goods Sold 81,082 35,163 158,926 72,169 Gross Profit 415,271 371,115 773,805 671,077 Operating Expenses: Research and development 4,201 2,263 9,963 2,263 Depreciation and amortization 14,881 14,881 29,761 29,761 Selling, general and administrative 345,043 337,793 695,741 632,407 Total Operating Expenses 364,125 354,937 735,465 664,431 Operating income 51,146 16,178 38,340 6,646 Other Income (Expense) Interest expense: Related Party (12,572) (12,841) (25,142) (24,872) Interest expense: Other (12,862) (13,327) (26,001) (26,665) Other income 4,544 Gain (loss) on foreign currency exchange 1 1 2 (149) Total Other Income (Expense) (25,433) (26,167) (51,141) (47,142) Income (Loss) Before Provision for Income Taxes 25,713 (9,989) (12,801) (40,496) Provision for income taxes - - - - Net Income (Loss) from continuing operations 25,713 (9,989) (12,801) (40,496) Loss from discontinued operations, net of tax (1,826) (49) (1,875) (150) Net Income (Loss) 23,887 (10,038) (14,676) (40,646) Preferred stock dividends - - (162,185) (162,185) Net Income (Loss) Available to Common Stockholders $23,887 ($10,038) ($176,861) ($202,831) Other Comprehensive Income (Loss) Foreign Currency Translation Adjustment - - - - Comprehensive Income (Loss) 23,887 (10,038) ($14,676) ($40,646) Income (Loss) Per Share - basic and diluted Income (Loss) from continuing operations $0.00 ($0.00) ($0.01) ($0.01) Loss from discontinued operations ($0.00) ($0.00) ($0.00) ($0.00) Income (Loss) available to common stockholders $0.00 ($0.00) ($0.01) ($0.01) Weighted Average Number of Shares Outstanding Basic 33,372,796 32,628,835 33,372,796 32,628,835 Weighted Average Number of Shares Outstanding Basic 38,667,862 32,628,835 33,372,796 32,628,835 VYCOR MEDICAL, Reconciliation of Operating Loss and Net Loss(unaudited) For the three months ended For the six months ended June 30, June 30, 2025 2024 2025 2024 GAAP Operating Expenses 364,125 354,937 735,465 664,431 Non-cash depreciation of purchased assets (1) (15,021) (15,681) (31,131) (31,301) Non-cash stock-based compensation (2) (18,314) - (36,629) (2,364) Total Non-GAAP Operating Expense Adjustments (33,335) (15,681) (67,760) (33,665) Non-GAAP Cash Operating Expenses $330,790 $339,256 $667,705 $630,766 GAAP Operating Profit (Loss) 51,146 16,178 38,340 6,646 Non-GAAP Operating Expense Adjustments, as above 33,335 15,681 67,760 33,665 Non-GAAP Operating Profit $84,481 $31,859 $106,100 $40,311 GAAP Net Income (Loss) available to common shareholders $23,887 $(10,038) $(176,861) $(202,831) Non-GAAP Operating Expense Adjustments, as above 33,335 15,681 67,760 33,665 Non-GAAP Net Income (Loss) available to common stockholders $57,222 $5,643 $(109,101) $(169,166) Non-GAAP Income (Loss) Per Share basic and diluted $0.00 $0.00 $(0.00) $(0.01) Weighted Average Number of Shares Outstanding Basic 33,372,796 32,628,835 33,372,796 32,628,835 Weighted Average Number of Shares Outstanding Diluted 38,667,862 32,628,835 33,372,796 32,628,835 (1) Non-Cash depreciation of purchased assetsThese are non-cash charges related to assets which can be impacted by the timing and magnitude of acquisitions. We consider our operating results without these charges when evaluating our ongoing costs and performance and therefore exclude such charges when presenting non-GAAP financial measures. (2) Non-Cash Stock-based compensation expense consists of expense relating to stock-based compensation issued to employees, outside directors and non-employees including stock options, restricted common stock, and warrants. Because of varying available valuation methodologies, subjective assumptions and the fact that these amounts vary in size and timing, we believe that the exclusion of stock-based compensation expense allows for a more accurate comparison of our financial results to previous periods. In addition, we believe it is useful to investors to understand the specific impact of stock-based compensation expenses on our operating results. About Vycor Medical, Inc. With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. ("Vycor") is a publicly traded company (OTCQB: VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared or registered medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Vycor Medical's FDA-cleared ViewSite(TM) Brain Access System (VBAS) a minimally invasive neurosurgical device designed to improve access to brain lesions while reducing tissue damage and enhancing patient outcomes. The VBAS system has been approved and used in over 300 hospitals in the US and in numerous countries internationally. VBAS is protected by 46 issued and 11 pending patents and has been validated through over 45 peer-reviewed studies. These studies demonstrate that use of VBAS results in: less brain tissue damage; less invasive procedure; improved access and better visibility; and reduced operating and recovery time. For an overview of Vycor Medical's VBAS see VBAS Video. NovaVision provides a suite of clinically supported vision rehabilitation therapies aimed at helping patients recover from visual impairments caused by stroke or other brain injury. The Visual Restoration Therapy (VRT) is the only commercialized FDA-cleared therapy for vision rehabilitation following neurological brain damage, making it a unique and important option for patients seeking to regain lost visual capabilities. The complementary NeuroEyeCoach program, clinically supported by a 296-patient study (the largest to date in the neuro visual space), enables dramatic improvements in patients' ability to detect objects in the visual field by training them to make better eye movements with improvement in over 80% of patients. The NovaVision therapies, while showing a positive impact on these patients' lives, still require significant development to allow them to successfully address their market potential. For an overview of NovaVision see NovaVision Video. For the latest information on the company, including media and other coverage, and to learn more, please go online at or in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law. Investor Relations Contacts: B2i Digital:David ShapiroChief Executive OfficerB2i Digital, Officedavid@ Vycor Medical, Inc. Contacts: 951 Broken Sound Parkway, Suite 320Boca Raton, FL. 33487(561) 558-2020info@ LinkedIn:
Forbes
27 minutes ago
- Forbes
What Is Vibrio Vulnificus? Deadly Warm-Water Bacteria Is Spreading In The Southeast.
Almost a dozen people have died this year in the Southeast after contracting a flesh-eating bacteria called Vibrio vulnificus that thrives in warm water and can be exacerbated by hurricanes hitting the coast. An oyster on May 19, 2024. AFP via Getty Images Health departments in several states are warning residents about a mysterious and unusual rise in the bacteria after dozens of cases were confirmed across 11 states and at least nine deaths were attributed to an infection, with a tenth attributed to another vibrio species. At least 57 cases have been confirmed this year, according to Today, with the highest numbers in Louisiana (17), Florida (13) and North Carolina (7). Five people have died from Vibrio vulnificus infections in Florida and four have died in Louisiana, but it's still unclear how exactly the victims contracted the bacteria, which can be spread through infected sea water or through eating raw or undercooked shellfish. The bacteria thrives in warm water, meaning summertime is the most common time for infections, but one expert told NBC News the number of deaths is still high for this point in the season and another told Today that infections have been steadily rising for the last six to seven years. Get Forbes Breaking News Text Alerts: We're launching text message alerts so you'll always know the biggest stories shaping the day's headlines. Text 'Alerts' to (201) 335-0739 or sign up here : 'This is certainly not normal, that's one thing,' Jantarpreet Jutla, an engineering professor at the University of Florida, told NBC News. 'We haven't had that many cases early on in the summer for a very long time.' Vibrio are bacteria that naturally live in coastal waters and there are about a dozen different kinds of Vibrio that can lead to vibriosis infections, including vulnificus, which can cause severe and life-threatening infections. Vibrio bacteria thrive in warm seawater and particularly in brackish water—the mix of fresh and salt water found in estuaries and wetlands. How Are People Infected With Vibrio? People can get vibriosis after swallowing Vibrio or getting it in a wound. The Centers for Disease Control and Prevention says eating contaminated food is the most common way to contract a vibriosis infection, claiming it's responsible for more than half of the estimated vibriosis cases each year. Oysters and other shellfish are the most common carriers of Vibrio. People with open wounds can also be exposed to Vibrio through direct contact with seawater and some infections, like of Vibrio vulnificus, can lead to necrotizing fasciitis that kills the flesh around an open would, leading to the moniker "flesh-eating bacteria." There is no evidence that vibriosis is transmissible person to person. What Are The Symptoms Of Vibrio Vulnificus? Those who contracted the infection following the ingestion of raw seafood typically present with fever, chills, blistering skin lesions or dangerously low blood pressure. Wound infections typically come with fever, redness, pain, swelling, discharge and discoloration. Vibrio vulnificus infections are diagnosed by stool, wound or blood cultures. How Deadly Is Vibrio Vulnificus? A Vibrio vulnificus infection can lead to serious illness and need intensive care or limb amputation. About one in five people with the infection die, sometimes within a day or two of becoming sick, according to the CDC. Vibrio vulnificus infections tend to increase after hurricanes. Paul Gulig, a professor and member of the University of Florida Emerging Pathogens Institute, credits Hurricanes Katrina, Irma and Ian with increasing the visibility of the bacteria. When brackish hurricane waters flooded the streets, cases of the bacterial infection rose. Florida saw a total of 82 cases last year (up from 46 in 2023) after its busy hurricane season. The National Weather Service has predicted a slightly above-normal season for this year thanks to warm ocean temperatures. NOAA estimates there will be between 13 and 19 named storms this year, with six to 10 developing into hurricanes. Further Reading Forbes New Virus Outbreak In China: What To Know About The Chikungunya Virus By Mary Whitfill Roeloffs Forbes Legionnaires' Disease Threatens NYC Again—Here's What Causes It And Who's Most At Risk By Zachary Folk
